English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

IT is well known that whereas folic acid antagonists may induce temporary remissions in various forms of malignant disease, apparently permanent remissions can be obtained in a high proportion of patients with choriocarcinoma. Broquist (1956) and Hiatt, Goldstein and Tabor (1958) observed that patients receiving a folic acid antagonist for leukaemia showed an abnormal excretion of formiminoglutamic acid in patients with various forms of cancer before any form of therapy. It has also been reported that patients with cancer, including the leukaemias, frequently have low serum folate values (Rao et al., 1965) but others have suggested that this correlated with nutritional status (Hellman, Iannotti and Bertino, 1964) and that the serum folate was not more depressed than in comparable hospital patients with non-malignant disease (Spector, Hutter and Fedorko, 1966). In the present paper we report the serum folate and formiminoglutamic acid excretion of patients with trophoblastic tumours. Changes in formiminoglutamic acid (FIGLU) excretion during treatment with the folic acid antagonist methotrexate have also been studied in some of these patients.

Serum folate and FIGLU excretion in patients with trophoblastic tumours